Dementia and Alzheimer's Disease Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors [Donepezil, Galantamine, Rivastigmine], Memantine, Combination Drugs [Memantine & Donepezil]), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Region, Forecast & Opportunities, 2028
Market Report I 2022-12-01 I 112 Pages I TechSci Research
Global dementia and Alzheimer's disease treatment market is expected to grow at impressive growth during the forecast period, 2024-2028. The increasing cases of Alzheimer's and dementia coupled with growing awareness regarding the diseases are bolstering the growth of the market. Moreover, elderly population are more prone to such diseases due to growing age, which in turn, is expected to positively impact the growth of market. Also, upsurge in R&D activities associated with disease, the introduction of new and innovative technologies and drugs, and increasing government initiatives such as investments, awareness programmes are expected to bolster the growth of market over the next few years. For instance, in 2022, a new initiative by McGill University's Dementia Education Program received funding from the Public Health Agency of Canada to raise awareness of dementia and promote dementia-inclusive communities.
The global dementia and Alzheimer's disease treatment market is segmented into drug class, distribution channel, company and region. Based on drug class, the market is categorized into cholinergic/cholinesterase (ChE) inhibitors, memantine, and combination drugs. Out of these, the cholinergic/cholinesterase (ChE) inhibitor segment dominates the dementia and Alzheimer's disease market. This is accredited to fact that it is first line of treatment for AD and most widely prescribed drug for the treatment. In addition, the drug is very effective for treating mild to severe dementia, which is contributing to the increasing growth of the segment.
The memantine segment is further expected to be the fastest growing segment during the forecast period. This is ascribed to its suitability in cholinergic/cholinesterase inhibitors intolerant patients suffering from AD.
Major players operating in the global dementia and Alzheimer's disease treatment market include Merz Pharma GmbH & Co. KGaA, Novartis AG, Pfizer, Inc., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., AbbVie Inc., Eli Lilly and Company, and Corium, Inc. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, thereby helping the industry to solve existing challenges and meet the needs of the market.
Objective of the Study:
- To analyze and estimate the market size of global dementia and Alzheimer's disease treatment market from 2018 to 2021.
- To estimate and forecast the market size of global dementia and Alzheimer's disease treatment market from 2022 to 2028 and growth rate until 2028.
- To classify and forecast global dementia and Alzheimer's disease treatment market based on drug class, distribution channel, company and regional distribution.
- To identify dominant region or segment in the global dementia and Alzheimer's disease treatment market.
- To identify drivers and challenges for global dementia and Alzheimer's disease treatment market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global dementia and Alzheimer's disease treatment market.
- To conduct pricing analysis for global dementia and Alzheimer's disease treatment market.
- To identify and analyze the profile of leading players operating in global dementia and Alzheimer's disease treatment market.
- to identify key sustainable strategies adopted by market players in global dementia and Alzheimer's disease treatment market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals and presence of all major players across the globe.
TechSci Research calculated the market size of global dementia and Alzheimer's disease treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:
- Dementia and Alzheimer's disease treatment facilities and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to dementia and Alzheimer's disease treatment
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, global dementia and Alzheimer's disease treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Global Dementia and Alzheimer's Disease Treatment Market, By Drug Class:
o Cholinergic/ Cholinesterase Inhibitors
- Donepezil
- Galantamine
- Rivastigmine
o Memantine
o Combination Drugs
- Memantine
- Donepezil
- Global Dementia and Alzheimer's Disease Treatment Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
- Global Dementia and Alzheimer's Disease Treatment Market, By Region:
o North America
- United States
- Canada
- Mexico
o Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
o Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
o Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
o South America
- Brazil
- Argentina
- Colombia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global dementia and Alzheimer's disease treatment market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Country
5.8. Clinical Trials Heat Map
6. Global Dementia and Alzheimer's Disease Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors [Donepezil, Galantamine, Rivastigmine], Memantine, Combination Drugs [Memantine & Donepezil]
6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
6.2.3. By Company (2022)
6.2.4. By Region
6.3. Market Attractiveness Index
7. Asia-Pacific Dementia and Alzheimer's Disease Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Dementia and Alzheimer's Disease Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Distribution Channel
7.3.2. India Dementia and Alzheimer's Disease Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Distribution Channel
7.3.3. Australia Dementia and Alzheimer's Disease Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Distribution Channel
7.3.4. Japan Dementia and Alzheimer's Disease Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Distribution Channel
7.3.5. South Korea Dementia and Alzheimer's Disease Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Distribution Channel
8. Europe Dementia and Alzheimer's Disease Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. Europe: Country Analysis
8.3.1. France Dementia and Alzheimer's Disease Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Distribution Channel
8.3.2. Germany Dementia and Alzheimer's Disease Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Distribution Channel
8.3.3. United Kingdom Dementia and Alzheimer's Disease Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Distribution Channel
8.3.4. Italy Dementia and Alzheimer's Disease Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Distribution Channel
8.3.5. Spain Dementia and Alzheimer's Disease Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Distribution Channel
9. North America Dementia and Alzheimer's Disease Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. North America: Country Analysis
9.3.1. United States Dementia and Alzheimer's Disease Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Distribution Channel
9.3.2. Mexico Dementia and Alzheimer's Disease Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Distribution Channel
9.3.3. Canada Dementia and Alzheimer's Disease Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Distribution Channel
10. South America Dementia and Alzheimer's Disease Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Dementia and Alzheimer's Disease Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Distribution Channel
10.3.2. Argentina Dementia and Alzheimer's Disease Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Distribution Channel
10.3.3. Colombia Dementia and Alzheimer's Disease Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Distribution Channel
11. Middle East and Africa Dementia and Alzheimer's Disease Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Class
11.2.2. By Distribution Channel
11.2.3. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Dementia and Alzheimer's Disease Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Class
11.3.1.2.2. By Distribution Channel
11.3.2. Saudi Arabia Dementia and Alzheimer's Disease Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Class
11.3.2.2.2. By Distribution Channel
11.3.3. UAE Dementia and Alzheimer's Disease Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Class
11.3.3.2.2. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Merz Pharma GmbH & Co. KGaA
14.2. Novartis AG
14.3. Pfizer, Inc.
14.4. Ono Pharmaceutical Co., Ltd.
14.5. Johnson & Johnson Services, Inc.
14.6. H. Lundbeck A/S
14.7. F. Hoffmann-La Roche Ltd.
14.8. AbbVie Inc.
14.9. Eli Lilly and Company
14.10. Corium, Inc.
15. Strategic Recommendations
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.